CP-532,903

From WikiMD.org
Jump to navigation Jump to search

CP-532,903

CP-532,903 (pronunciation: C-P-five-three-two-nine-zero-three) is a pharmaceutical drug developed by Pfizer for the potential treatment of myocardial infarction, also known as a heart attack.

Etymology

The name "CP-532,903" is a unique identifier given by the developing company, Pfizer. The "CP" stands for Central Pharmaceuticals, a division of Pfizer. The number "532,903" is a sequential number assigned to the compound during its development.

Mechanism of Action

CP-532,903 is a selective adenosine A3 receptor agonist. Adenosine A3 receptors are a subtype of adenosine receptors, which are a group of G protein-coupled receptors with adenosine as their endogenous ligand. By activating these receptors, CP-532,903 can increase coronary blood flow, reduce myocardial oxygen consumption, and limit the size of a myocardial infarction.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski